Clinical feature |
N |
RIZ1
unmethylated |
% |
RIZ1
methylated |
% |
P Value |
Patients |
100 |
91 |
91% |
9 |
9% |
0.06 |
Controls |
50 |
50 |
100% |
0 |
0% |
|
Age >45 |
36 |
33 |
91.6% |
3 |
8.4% |
0.98 |
Age <45 |
64 |
58 |
90.6% |
6 |
9.4% |
|
Males |
65 |
58 |
89.2% |
7 |
10.7% |
0.63 |
Female |
35 |
33 |
94.2% |
2 |
5.8% |
|
CP-CML |
48 |
46 |
95.8% |
2 |
4.2% |
|
AP-CML |
28 |
27 |
96.4% |
1 |
3.6% |
0.009 |
BC-CML |
24 |
18 |
75% |
6 |
25% |
|
b2a2 |
31 |
29 |
93.5% |
2 |
6.5% |
|
b3a2 |
67 |
60 |
89.5% |
7 |
10.5% |
0.73 |
A2b2/ A2b3 |
2 |
2 |
100% |
0 |
0% |
|
MMR |
52 |
51 |
98.08% |
01 |
1.92% |
0.03 |
Loss of MR |
48 |
40 |
83.33% |
8 |
16.77% |
|
MHR |
50 |
49 |
98% |
01 |
2% |
0.01 |
Minor HR |
10 |
07 |
70% |
03 |
30% |
|
Minimal HR |
40 |
35 |
85% |
05 |
12.50% |
|
Imatinib alone |
90 |
84 |
93.33% |
6 |
6.66% |
0.02 |
Imatinib+Dasatanib |
07 |
06 |
85.70% |
1 |
14.30% |
|
Interferon |
03 |
01 |
33.33% |
2 |
66.66% |
|
Thrombocytopenia |
60 |
54 |
90% |
6 |
10% |
0.9 |
No Thrombocytopenia |
40 |
37 |
92.5% |
3 |
7.5% |
|
MR:Molecular response, HR: Hematological response |